NasdaqCM - Delayed Quote USD

BioRestorative Therapies, Inc. (BRTX)

1.7300

+0.0100

+(0.58%)

At close: April 23 at 4:00:02 PM EDT

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern time. Benzinga All-Access Show Date: Tuesday, April 15, 2025Time: 10:50 a.m.

GlobeNewswire 8 days ago

BRTX
+0.58%
BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to confirm that it currently faces no material exposure to newly imposed U.S. tariffs. BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is BioRestorative’s lead clinical candidate. The saf

GlobeNewswire 13 days ago

BRTX
+0.58%
BioRestorative Therapies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioRestorative Therapies ( NASDAQ:BRTX ) Full Year 2024 Results Key Financial Results Net loss: US$8.98m (loss narrowed...

Simply Wall St. 25 days ago

BRTX
+0.58%
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business. “2024 was a transformative year for BioRestorative, highlighted by significantly improved financial performance and meaningful clinical program advancement,” said L

GlobeNewswire 27 days ago

BRTX
+0.58%
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025

MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its 2024 financial results after market close on Thursday, March 27, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. 20

GlobeNewswire last month

BRTX
+0.58%
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company’s advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain – – Company to host webcasted conference call today at 10:30am EST – MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative

GlobeNewswire last month

BRTX
+0.58%
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today that it has changed the time for its previously announced webcasted conference call to discuss its pipeline update. The Company will now host the call at 10:30am EST on Thursday, February 27, 2025. To participate in the conference call by telep

GlobeNewswire last month

BRTX
+0.58%
BioRestorative to Provide a Positive FDA Update on Clinical Pipeline

MELVILLE, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that it expects to provide a positive clinical pipeline update before market open on Thursday, February 27, 2025. “We very much look forward to updating investors on some recent meaningful key developments with respect to our clinical pi

GlobeNewswire last month

BRTX
+0.58%
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date – – May also lead to Priority Review and Accelerated Biologics License Application (“BLA”) Approval for BRTX-100 – MELVILLE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on ste

GlobeNewswire 2 months ago

BRTX
+0.58%
BRTX-100 Front and Center at ORS 2025

– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health” presentation – – Among other positive preliminary data analyses, comparison of MRI images to baseline potentially demonstrate disc microenvironment remodeling – MELVILLE, N.Y., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on st

GlobeNewswire 2 months ago

BRTX
+0.58%
BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Shift From Loss To Profit

We feel now is a pretty good time to analyse BioRestorative Therapies, Inc.'s ( NASDAQ:BRTX ) business as it appears...

Simply Wall St. 2 months ago

BRTX
+0.58%
Pleasing Signs As A Number Of Insiders Buy BioRestorative Therapies Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 3 months ago

BRTX
+0.58%
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

– Covers cGMP manufacturing processes – – Expected to provide protection until April 29, 2040 – MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that the European Patent Office has issued a Notice of Allowance for a new patent application (European Patent Appl. No. 20798130.9) covering

GlobeNewswire 4 months ago

BRTX
+0.58%
BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioRestorative Therapies ( NASDAQ:BRTX ) Third Quarter 2024 Results Key Financial Results Net loss: US$1.09m (loss...

Simply Wall St. 5 months ago

BRTX
+0.58%
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in function – – If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Secondary end points - – The blinded preliminary BRTX-100 data to be described in a podium presentation this morning at the ORS PSRS 7th International Spine Research Symposium – – Webcasted confe

GlobeNewswire 5 months ago

BRTX
+0.58%
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the third quarter ended September 30, 2024 and provided an update on its business. “We have continued to execute well across all areas of our business and are looking forward to continuing to update investors on our progress as we close o

GlobeNewswire 5 months ago

BRTX
+0.58%
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium

– New blinded preliminary safety and efficacy data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in podium presentation on November 13, 2024 – – Data will be on a significantly higher number of study subjects over a longer period of time than has been presented previously -– – Company will also release its third quarter 2024 financial results and provide a business update on November 12, 2024 – – Webcasted conference call to review both the BRTX-100 data and Q3-2024 financi

GlobeNewswire 5 months ago

BRTX
+0.58%
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has received a provisional license from the New York State Department of Health (“NYSDOH”) for the processing

GlobeNewswire 5 months ago

BRTX
+0.58%
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program

– Further expands already formidable intellectual property estate the Company has been building for its novel ThermoStem® technology platform – MELVILLE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that the Israel Patent Office has issued a Notice of Allowance for a new patent application (

GlobeNewswire 5 months ago

BRTX
+0.58%
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events

MELVILLE, N.Y., Oct. 10, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, announces the following investor events in October: UBS Virtual Organ Restoration and Cell Therapy Day: Lance Alstodt, BioRestorative’s Chief Executive Officer, will participate in a fireside chat with UBS’ SMID-cap Biotech & Specialty Pharma Analyst, Ash Verma, on October 1

GlobeNewswire 6 months ago

BRTX
+0.58%

Performance Overview

Return	BRTX	S&P 500 (^GSPC)
YTD	+20.98%	-8.60%
1-Year	+29.10%	+6.02%
3-Year	-59.77%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioRestorative Therapies, Inc. (BRTX)

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

BioRestorative Therapies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

BioRestorative to Provide a Positive FDA Update on Clinical Pipeline

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

BRTX-100 Front and Center at ORS 2025

BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Shift From Loss To Profit

Pleasing Signs As A Number Of Insiders Buy BioRestorative Therapies Stock

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program

BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events

Performance Overview